Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 213Myelodysplastic Syndromes 82Leukemia 44Leukemia, Myelomonocytic, Chronic 35Recurrence 16Myeloproliferative Disorders 15Neoplasm, Residual 10Lymphoma, T-Cell, Peripheral 10Leukemia, Biphenotypic, Acute 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large B-Cell, Diffuse 7Anemia, Refractory, with Excess of Blasts 7Primary Myelofibrosis 6Lymphoma, Non-Hodgkin 6Hodgkin Disease 6Congenital Abnormalities 6Lymphoma, T-Cell 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Monocytic, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Polycythemia Vera 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Follicular 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Myeloid 4

Interventions

Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myeloid Malignancy × Azacitidine × Clear all
NCT03850418 2026-02-24

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Henry Ford Health System

Phase 2 Recruiting
43 enrolled

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡